Dai Maruyama

53PUBLICATIONS
62CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Medical mycologyOncology and carcinogenesis not elsewhere classifiedCancer therapy (excl. chemotherapy and radiation therapy)Cancer diagnosis
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (53)

|Jun 15, 2026
Efficacy and safety of subcutaneous mosunetuzumab plus polatuzumab vedotin in patients with relapsed/refractory large B-cell lymphoma: Japan subgroup analysis of the phase III SUNMO trial.

|Apr 14, 2026
Extracellular Vesicle IL5RA and BCMA in Serum Enable Non-Invasive Risk Stratification of Multiple Myeloma.

Yuko Shirouchi, Hiroki Shinchi, Yoshimi Haga

|Feb 11, 2026
Long-term clinical outcomes of patients with localized primary ocular adnexal mucosa-associated lymphoid tissue lymphoma.

Ritsuko Nakai, Dai Maruyama, Akiko Miyagi-Maeshima

|Jan 27, 2026
Novel agents and therapeutic advances in T cell lymphoma.

Yuko Shirouchi, Dai Maruyama

|Dec 20, 2025
Impact of Achieving Progression-Free Survival 24 on Subsequent Overall Survival in Diffuse Large B-Cell Lymphoma Patients.

Ayumi Fujimoto, Wataru Munakata, Gakuto Ogawa

|Dec 16, 2025
Protocol digest of a randomized phase III study of pola-R-CHP/high-dose methotrexate/IT vs. pola-R-CHP/IT for newly diagnosed diffuse large B-cell lymphoma with high risk of central nervous system relapse: JCOG2201 (PREMIER).

Yusuke Sano, Kana Miyazaki, Motoko Yamaguchi

Pageof 9

Frequent Collaborators

7 joint publications

Shinichi Makita

6 joint publications

Shinsuke Iida

6 joint publications

Kana Miyazaki

6 joint publications

Junya Kuroda